What's behind <sup>68</sup>Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.

Rüschoff, Jan H; Ferraro, Daniela A; Muehlematter, Urs J; Laudicella, Riccardo; Hermanns, Thomas; Rodewald, Ann-Katrin; Moch, Holger; Eberli, Daniel et al. · Eur J Nucl Med Mol Imaging · 2021

retrospective_cohort · Level III

Where this comes from

Abstract

Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. We investigated histopathological parameters and immunohistochemical PSMA expression patterns on radical prostatectomy (RPE) specimens and correlated them to the corresponding <sup>68</sup>Ga-PSMA-11-PET examinations. RPE specimens of 62 patients with preoperative <sup>68</sup>Ga-PSMA-11-PET between 2016 and 2018 were analysed. WHO/ISUP grade groups, growth pattern (expansive vs. infiltrative), tumour area and diameter as well as immunohistochemical PSMA heterogeneity, intensity and negative tumour area (PSMA<sub>%neg</sub>) were correlated with spatially corresponding SUV<sub>max</sub> on <sup>68</sup>Ga-PSMA-11-PET in a multidisciplinary analysis. All tumours showed medium to strong membranous (2-3 +) and weak to strong cytoplasmic (1-3 +) PSMA expression. Heterogeneously expressed PSMA was found in 38 cases (61%). Twenty-five cases (40%) showed at least 5% and up to 80% PSMA<sub>%neg</sub>. PSMA<sub>%neg</sub>, infiltrative growth pattern, smaller tumour area and diameter and WHO/ISUP grade group 2 significantly correlated with lower SUV<sub>max</sub> values. A ROC curve analysis revealed 20% PSMA<sub>%neg</sub> as an optimal cutoff with the highest sensitivity and specificity (89% and 86%, AUC 0.923) for a negative PSMA-PET scan. A multiple logistic regression model revealed tumoural PSMA<sub>%neg</sub> (p < 0.01, OR = 9.629) and growth pattern (p = 0.0497, OR = 306.537) as significant predictors for a negative PSMA-PET scan. We describe PSMA<sub>%neg</sub>, infiltrative growth pattern, smaller tumour size and WHO/ISUP grade group 2 as parameters associated with a lower <sup>68</sup>Ga-PSMA-11 uptake in prostate cancer. These findings can serve as fundament for future biopsy-based biomarker development to enable an individualized, tumour-adapted imaging approach.

Medical subject headings